½ÃÀ庸°í¼­
»óǰÄÚµå
1668770

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àü°Ô³ð ¹× ¿¢¼Ø ½ÃÄö½Ì ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º° - ºÐ¼®°ú ¿¹Ãø(2024-2033³â)

Asia-Pacific Whole Genome and Exome Sequencing Market: Focus on End User and Country - Analysis and Forecast, 2024-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: BIS Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àü°Ô³ð ¹× ¿¢¼Ø ½ÃÄö½Ì ½ÃÀå ±Ô¸ð´Â 2024³â 4¾ï 2,590¸¸ ´Þ·¯¿¡¼­ 2033³â¿¡´Â 17¾ï 8,480¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2024-2033³â ¿¬Æò±Õ 15.13%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

WGS°¡ Àüü À¯ÀüüÀ» ºÐ¼®ÇÏ´Â ¹Ý¸é, WES´Â Áúº´°ú °ü·ÃµÈ º¯ÀÌüÀÇ ´ëºÎºÐÀ» Æ÷ÇÔÇÏ´Â ´Ü¹éÁú ÄÚµå ¿µ¿ª¿¡ ÁýÁßÇÕ´Ï´Ù. ºñ¿ëÀÌ ³·¾ÆÁö°í ¿ëµµ°¡ È®´ëµÊ¿¡ µû¶ó ÀÌµé ±â¼úÀº Á¡Á¡ ´õ ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
¿¹Ãø ±â°£ 2024-2033³â
2024³â Æò°¡ 4¾ï 2,590¸¸ ´Þ·¯
2033³â ¿¹Ãø 17¾ï 8,480¸¸ ´Þ·¯
CAGR 17.26%

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀüÀåÀ¯Àüü ¹× ¿¢¼Ø ½ÃÄö½Ì ½ÃÀåÀº À¯ÀüüÇÐÀÇ ¹ßÀü, À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó Áø´Ü, ¸ÂÃãÇü Ä¡·á, »ý¹° ÀÇÇÐ ¿¬±¸´Â ¸ðµÎ »ç¶÷ÀÇ DNA¸¦ öÀúÇÏ°Ô °Ë»çÇÏ´Â ÀüÀåÀ¯Àüü ¿°±â¼­¿­ ºÐ¼®(WGS)°ú ´Ü¹éÁúÀ» ¾ÏȣȭÇÏ´Â ¿µ¿ª¿¡ ÁýÁßÇÏ´Â ÀüÀå¿¢¼Ø ¿°±â¼­¿­ ºÐ¼®(WES)¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù.

Áß±¹, ÀϺ», Çѱ¹, Àεµ µîÀÇ ±¹°¡´Â Á¤ºÎÀÇ °­·ÂÇÑ ±¸»ó, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ºÐ¾ßÀÇ ¼ºÀå, ÀÇ·á Á¦°øÀÚ¿Í ¿¬±¸±â°üÀÇ ÆÄÆ®³Ê½Ê È®´ë·Î ÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ½ÃÄö½Ì ±â¼úÀÇ ºñ¿ë °¨¼Ò, ºòµ¥ÀÌÅÍ ºÐ¼® ¹× ÀΰøÁö´É(AI)ÀÇ È°¿ëÀ¸·Î ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

»ý½ÄÀÇÇÐ, ¾à¹°À¯ÀüüÇÐ, Á¾¾çÇÐ, Èñ±ÍÁúȯ Áø´ÜÀÌ Áß¿äÇÑ ¿ëµµÀÔ´Ï´Ù. ½ÃÀå ¼ö¿ä´Â ¼ÒºñÀÚ Á÷Á¢ ÀÇ·Ú(DTC) °Ë»ç ¼­ºñ½ºÀÇ ºÎ»ó°ú À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¿¡ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ±×·¯³ª µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã, º¹ÀâÇÑ ±ÔÁ¦, µµ´öÀû µô·¹¸¶ µîÀÇ ¹®Á¦´Â ¿©ÀüÈ÷ ³²¾ÆÀÖ½À´Ï´Ù.

À̸¦ °í·ÁÇÒ ¶§, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀüÀå À¯Àüü ¹× ¿¢¼Ø ½ÃÄö½Ì ½ÃÀåÀº ±â¼ú ¹ßÀü, ÀÇ·á ºñ¿ë »ó½Â, Á¤È®ÇÑ µ¥ÀÌÅͺ£À̽º ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àü°Ô³ð ¹× ¿¢¼Ø ½ÃÄö½Ì ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀåÀÇ °³¿ä¿Í ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º° µ¿Çâ ¹× ½ÃÀå¿¡ Âü¿©ÇÏ´Â ±â¾÷ÀÇ °³¿ä µîÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

°³¿ä

Á¦1Àå ¾÷°è Àü¸Á

  • ½ÃÀå µ¿Çâ
  • ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ
  • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
  • °ø±Þ¸Á ºÐ¼®
  • ½ÃÀå ¿ªÇÐÀÇ °³¿ä

Á¦2Àå Áö¿ª

  • Áö¿ªº° °³¿ä
  • ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦3Àå ½ÃÀå - °æÀï º¥Ä¡¸¶Å·°ú ±â¾÷ °³¿ä

  • ÁÖ¿ä Àü·«°ú °³¹ß
  • ±â¾÷ °³¿ä
    • BGI Group(Beijing Genomics Institute(BGI))
    • Novogene Corporation

Á¦4Àå Á¶»ç ¹æ¹ý

KSA 25.03.19

Introduction to Asia-Pacific Whole Genome and Exome Sequencing Market

The Asia-Pacific whole genome and exome sequencing market is projected to reach $1,784.8 million by 2033 from $425.9 million in 2024, growing at a CAGR of 15.13% during the forecast period 2024-2033. WGS analyses the entire genome, whereas WES concentrates on protein-coding regions that contain the majority of disease-related variants. As costs come down and applications increase, these technologies are becoming more and more popular.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2024 - 2033
2024 Evaluation$425.9 Million
2033 Forecast$1,784.8 Million
CAGR17.26%

The market for whole genome and exome sequencing in Asia-Pacific (APAC) is expanding quickly due to advances in genomics, an increase in the prevalence of genetic disorders, and growing investments in precision medicine. Clinical diagnostics, customised treatments, and biomedical research all depend on whole genome sequencing (WGS), which offers a thorough examination of a person's DNA, and whole exome sequencing (WES), which concentrates on protein-coding regions.

With robust government initiatives, growing biotechnology sectors, and growing partnerships between healthcare providers and research institutions, nations like China, Japan, South Korea, and India are leading this market. The market is expanding due to the declining cost of sequencing technologies, as well as the use of big data analytics and artificial intelligence (AI).

Reproductive health, pharmacogenomics, oncology, and rare disease diagnosis are important applications. Demand in the market is also being influenced by the rise of direct-to-consumer (DTC) testing services and increased awareness of genetic testing. But there are still issues like data privacy, complicated regulations, and moral dilemmas.

All things considered, the APAC whole genome and exome sequencing market is expected to grow significantly due to advancements in technology, rising healthcare costs, and the growing demand for accurate, data-driven medical solutions.

Market Segmentation:

Segmentation 1: by End User

  • Pharmaceutical and Biotechnology Companies
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Research and Academic Institutes
  • Others

Segmentation 2: by Country

  • Japan
  • India
  • China
  • Singapore
  • Australia
  • Rest-of-Asia-Pacific

How can this report add value to an organization

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements and emerging applications in genome and exome sequencing, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • BGI Group
  • Novogene Corporation

Table of Contents

Executive Summary

Scope and Definition

1 Industry Outlook

  • 1.1 Market Trends
    • 1.1.1 Technological Innovations in the Sequencing Technology
    • 1.1.2 Numerous Inorganic Growth Activities in the Market
  • 1.2 COVID-19 Impact on Market
  • 1.3 Regulatory Framework
    • 1.3.1 Legal Requirements and Framework in Japan
  • 1.4 Supply Chain Analysis
  • 1.5 Market Dynamics Overview
    • 1.5.1 Market Drivers
      • 1.5.1.1 Growing Applications of Whole Genome and Exome Sequencing in Clinical Diagnostics
      • 1.5.1.2 Rising Demand for Personalized Medicine Influencing the Demand for Whole Genome and Exome Sequencing
      • 1.5.1.3 Lowering Costs and Increasing Accessibility of Genome Sequencing
      • 1.5.1.4 Ongoing Whole Genome Sequencing Government Initiatives around the World
    • 1.5.2 Market Restraints
      • 1.5.2.1 Privacy and Ethical Concerns due to Increased Risk of Security Breaches
    • 1.5.3 Market Opportunities
      • 1.5.3.1 Increasing Usage of Sequencing Technology in Emerging Markets

2 Region

  • 2.1 Regional Summary
  • 2.2 Asia-Pacific
    • 2.2.1 Regional Overview
    • 2.2.2 Driving Factors for Market Growth
    • 2.2.3 Factors Challenging the Market
      • 2.2.3.1 By End User
    • 2.2.4 China
    • 2.2.5 India
    • 2.2.6 Australia
    • 2.2.7 Japan
    • 2.2.8 Singapore
    • 2.2.9 Rest-of-Asia-Pacific

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Key Strategies and Development
  • 3.2 Company Profiles
    • 3.2.1 BGI Group (Beijing Genomics Institute (BGI))
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Key Personnel
      • 3.2.1.5 Analyst View
    • 3.2.2 Novogene Corporation
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products/Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Key Personnel
      • 3.2.2.5 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦